Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus

被引:0
作者
Phil McEwan
Samantha Webster
Thomas Ward
Michael Brenner
Anupama Kalsekar
Yong Yuan
机构
[1] Health Economics & Outcomes Research Ltd,School of Human & Health Sciences
[2] Swansea University,undefined
[3] UK HEOR,undefined
[4] Bristol–Myers Squibb Pharmaceuticals Ltd,undefined
[5] World Wide Health Economics and Outcomes Research,undefined
[6] Bristol–Myers Squibb Pharmaceuticals Ltd,undefined
来源
Cost Effectiveness and Resource Allocation | / 15卷
关键词
Hepatitis C virus; Daclatasvir; Cost-effectiveness; Sofosbuvir;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 124 条
[1]  
Kanwal F(2010)Increasing prevalence of HCC and Cirrhosis in patients with chronic hepatitis C virus infection Gastroenterology 140 1182-1188
[2]  
Hoang T(2009)Association between hepatitis C and hepatocellular carcinoma J Glob Infect Dis 1 33-37
[3]  
Kramer JR(2009)Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C J Hepatol 51 655-666
[4]  
Asch SM(2011)Role of hepatitis C virus genotype 3 in liver fibrosis progression—a systematic review and meta-analysis J Viral Hepat 18 745-759
[5]  
Goetz MB(2010)Adverse outcomes in Alaska natives who recovered from or have chronic hepatitis C infection Gastroenterology 138 922-931
[6]  
Zeringue A(2010)Hepatitis C virus genotype 3 and the risk of severe liver disease in a large population of drug users in France J Med Virol 82 1647-1654
[7]  
de Oliveria Andrade LJ(2012)Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis JAMA 308 2584-2593
[8]  
D’Oliveira A(2011)HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis J Viral Hepat 18 e516-e522
[9]  
Melo RC(2014)HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of US Veterans with HCV Hepatology 60 98-105
[10]  
De Souza EC(2015)EASL recommendations on treatment of hepatitis C 2015 J Hepatol 63 199-63